NJ-OPENLEGACY
29.6.2021 14:02:13 CEST | Business Wire | Press release
OpenLegacy , which transforms monolithic mainframe systems into cloud-native building blocks of innovation, today announced their selection by top French retail chain Monoprix as its API integration platform of choice. Monoprix, a Casino Group brand, is leveraging the OpenLegacy Composable Integration Platform to access its mainframe Z series systems quickly, easily and reliably.
“We needed faster time-to-market since we frequently introduce new fashion collections,” states Monoprix CIO Vincent Cotteaux. “OpenLegacy helped us make the necessary digital-driven integrations to our mainframe Z O/S systems to meet these pressing needs and improve our overall data quality.”
“OpenLegacy empowers Monoprix to simplify the whole process of API creation to enable more team members with diverse skills and backgrounds to be equal contributors to the new API factory,” explains OpenLegacy EMEA General Manager Gil Cohen. “This project demonstrates the flexibility of exposing APIs, properly organized by domains and crafted based on a well-designed granularity. The quick turnaround of the project proves that OpenLegacy enables fast API design while delivering ultra-high quality.”
This customer acquisition builds upon OpenLegacy’s growing traction in the global retail industry. OpenLegacy’s benefits for this sector where the need for digital agility has never been greater include:
- Providing a 360-degree view of the customer interaction with the retailer that incorporates any data stored in their mainframes
- Enabling instant quote approvals for sales reps on the floor in conjunction with their managers
- Delivering the ability to track inventory and make current data available on any device even when it is stored on the mainframe
Monoprix is achieving faster time-to-market with its frequent introduction of new fashion collections by leveraging OpenLegacy to access their mainframe Z O/S systems and expose its transactions as microservices-based APIs. Monoprix has already gone live with a strategic project in collaboration with OpenLegacy, using OpenLegacy to simplify, automate and enable non-developer users to start designing APIs from complex core applications that will further support their business growth.
To learn more about OpenLegacy’s composable integration technology, visit www.openlegacy.com .
About OpenLegacy
OpenLegacy’s Digital-Driven Integration enables organizations with legacy systems to release new digital services faster and more efficiently than ever before. It connects directly to even the most complex legacy systems, bypassing the need for extra layers of technology. It then automatically generates APIs in minutes, rapidly integrating those assets into new and exciting innovations. Finally, it deploys them as standard microservices or serverless functions, giving organizations speed and flexibility while drastically cutting costs and resources. With OpenLegacy, industry leading companies release new apps, features, and updates in days instead of months, enabling them to truly become digital to the core. Learn why leading companies choose OpenLegacy at openlegacy.com , and follow us on Twitter or LinkedIn .
About Monoprix
Monoprix is a brand of the Casino Group. Leader in city-center retail in more than 250 cities in France, its 21,000 employees run 800 stores on a daily basis, with three brand formats – Monoprix, monop' and Naturalia – and two e-commerce sites, monoprix.fr and Sarenza, grouped within the Monoprix online entity. In 2020, Monoprix carried out 5 billion Euros in activities. Learn more at entreprise.monoprix.fr .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom